Revvity, formerly known as PerkinElmer, is a leading provider of health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure . The company operates through two main segments: Life Sciences and Diagnostics, offering a range of products including instruments, reagents, software, and services . Revvity's revenue is nearly evenly split between these segments, with a significant portion being recurring in nature .
-
Life Sciences Segment - Provides products and services targeted towards life sciences customers, focusing on preclinical research and development. Includes sales of instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training, and services .
-
Diagnostics Segment - Develops diagnostics, tools, and applications focused on clinically-oriented customers, particularly in reproductive health, emerging market diagnostics, and applied genomics. Generates revenue from instruments, solutions, consumables, reagents, and services, with significant growth driven by immunodiagnostics and reproductive health businesses .
You might also like
What went well
- Operating margins increased by 80 basis points year-over-year to 28.3% in the quarter, demonstrating strong execution and positive impact from strategic initiatives despite weak market conditions.
- Reagents business is returning to growth, with broad-based recovery across different product lines, indicating stabilization and improved demand in the market.
- Strong performance in the newborn screening and reproductive health segment, with global growth in the low double-digits driven by geographic and menu expansion, highlighting robust demand and market leadership.
What went wrong
- Delayed Recovery in Instrumentation Sales: The company is experiencing continued delays with instrument purchases, especially in China, as customers wait for stimulus funds, leading to a lower-than-expected end-of-year spending on capital equipment.
- Subdued Growth in China: Despite expectations, the rebound in China's market is more gradual, with the "Year of the Dragon" effect being less significant than in previous cycles, and life science markets in China facing flat growth expectations.
- Weakness in Biopharma and Academic Markets: Both biopharma and academic customer segments were down low single digits, indicating ongoing softness in key markets for the company's reagents business.
Q&A Summary
-
Fourth Quarter Outlook
Q: What's behind the increased caution for Q4?
A: The change in our organic growth outlook from 2% to 0%-1% is driven by weaker instrument sales, especially in China where customers are pausing as they await stimulus funding. While the U.S. market shows signs of returning to normal faster than other regions, China was a bigger drag than anticipated. ( ) -
2025 Growth Expectations
Q: Is 4% organic growth a good starting point for 2025?
A: We'll provide 2025 guidance at our Q4 call, but it appears the worst is behind us, and demand has started to recover. Normalization is likely to take us into the first half of 2025, but the rate of recovery remains to be seen. ( ) -
Instrument Sales in China
Q: Did things worsen or was recovery lacking in instruments?
A: We see sequential improvement and continued stabilization, but the path to normalization is more gradual than expected. Instruments in China performed worse due to delays in stimulus funding, now expected in early 2025, leading us to lower our instrument expectations for Q4 '24. ( ) -
Share Repurchase Authorization
Q: Will you be more active with share repurchases given the new authorization?
A: Yes, we plan to remain active with share repurchases. The Board approved a $1 billion repurchase authorization for the next two years, reflecting our strong cash flow, balance sheet stability, and confidence in future performance. ( ) -
Applied Genomics Guidance
Q: Is Applied Genomics expected to grow in Q4?
A: For Q4, we expect Applied Genomics to be roughly flat compared to Q3, and Life Sciences Instrumentation to decline mid-single digits. ( ) -
Reproductive Health Growth
Q: How did Reproductive Health perform, especially in China?
A: Our newborn business grew low-double digits globally, with China growing high-single digits. Growth is driven by commercial initiatives and some instrument placements; we expect a positive trend to continue despite a more subdued impact from the Year of the Dragon. ( ) -
China Immunodiagnostics
Q: How did Immunodiagnostics perform in China?
A: Immunodiagnostics in China performed as expected, with full-year growth anticipated at around mid-single digits. Our business differs from peers, so their headwinds aren't directly comparable to ours. ( ) -
Drug Discovery and Reagents
Q: What's the impact on drug discovery and reagents?
A: While instruments recovery is slower, reagents performed well, returning to mid-single-digit growth, in line with expectations. Our software business is expected to grow low double digits for the full year. ( ) -
China Stimulus Impact
Q: How did the lack of China stimulus affect you?
A: Although we didn't expect much from the stimulus, customers who would have purchased regardless also paused to see if they could obtain funding, resulting in worse performance in China. ( ) -
Reagents Business Strength
Q: What's driving the performance in reagents?
A: Our reagents business shows continued sequential improvement across a diverse portfolio, including BioLegend, Dharmacon, HTRF, and ELISA kits, performing well globally in pharma biotech applications. ( ) -
M&A and Capital Allocation
Q: How does the share repurchase affect your M&A plans?
A: We'll remain active in building a strong M&A pipeline, but current valuations haven't changed much. We see more value in our own stock right now and are taking advantage of that opportunity. ( ) -
China Market Sentiment
Q: What's the outlook for China demand in 2025?
A: Sentiment in China remains strong with optimism in our sector. The government is focused on economic recovery, and customers are positive about our products. Our "in China for China" strategy continues to work effectively. ( ) -
Operating Margin and Leverage
Q: How will recovery affect operating leverage?
A: Despite weak market conditions, we've increased our operating margin by 80 basis points year-over-year this quarter. As markets recover, we expect the strength of our portfolio to drive further improvements, with reagents showing signs of stabilization. ( ) -
Life Sciences Investments
Q: What are the investments affecting Life Sciences margins?
A: Investments include our GMP facility, e-commerce platform unification, and expansion of our Signals software portfolio. These strategic investments, while pressuring margins now, position us for future growth. ( ) -
TB Automation Launch Delay
Q: What's the status of the TB automation launch?
A: The U.S. launch of our TB automation has been pushed from Q4 2024 to Q1 2025 as we address certain questions, ensuring readiness for market introduction. ( ) -
Potential Election Impacts
Q: How might U.S. elections affect your China business?
A: We won't speculate on election outcomes. Regardless, our "in China for China" strategy has proven resilient through past cycles, and we're confident in our ability to continue serving customers in China. ( )
-
Given that your Life Sciences Instrumentation business is expected to decline mid-single digits in Q4 and Applied Genomics is projected to be flat, what specific steps are you taking to address these challenges and return these segments to growth?
-
Your reagents business grew mid-single digits while peers in the RUO antibodies market are still down; can you elaborate on what's driving your better-than-peer performance in reagents and how sustainable is this outperformance considering both biopharma and academic customers were down low single digits?
-
With the majority of your reagents focused on the preclinical side and considering ongoing pipeline rationalizations and cuts from large pharma, how exposed are you to potential reductions in preclinical R&D spending, and what strategies are you implementing to mitigate this risk?
-
You mentioned that instrument normalization is not happening as quickly as anticipated and recovery is slower; given these challenges, how confident are you in your forecast for similar reagent volumes in Q4, and what indicators support your outlook for market stabilization or recovery?
-
Despite peers flagging incremental headwinds in China immunodiagnostics, you've reported mid-single-digit growth and noted that your business is different; can you explain what differentiates your immunodiagnostics business in China and how you plan to sustain growth amid potential market headwinds?
Q3 2024 Earnings Call
- Issued Period: Q3 2024
- Guided Period: FY 2024
- Guidance:
- Organic Growth: Fourth quarter expected to be 3% to 5%; full year approximately 0% to 1% .
- Revenue: Full year expected to be $2.75 billion to $2.77 billion .
- Operating Margins: Full year 28% to 28.5%; fourth quarter over 30% .
- Net Interest Expense: Approximately $43 million for the full year .
- Tax Rate: Approximately 19% for the full year .
- Earnings Per Share (EPS): Full year $4.83 to $4.87 .
- Free Cash Flow: Approximately $550 million for the full year .
- Share Repurchase: New $1 billion authorization over the next 2 years .
Q2 2024 Earnings Call
- Issued Period: Q2 2024
- Guided Period: FY 2024
- Guidance:
- Organic Growth: 2% midpoint for the year .
- Revenue: Full year $2.77 billion to $2.79 billion .
- Adjusted EPS: $4.70 to $4.80 for the year .
- Adjusted Operating Margins: 28% to 28.5% for the year .
- Net Interest and Other Expense: Approximately $50 million for the year .
- Tax Rate: A little over 20% for the full year .
- Diluted Share Count: Approximately 123.5 million shares .
- FX Impact: Negative 1% headwind for the full year .
- Third Quarter Guidance:
- Organic Growth: Low single digits year-over-year .
- FX Impact: Headwind of approximately 100 basis points .
- Adjusted Operating Margins: Around 28% .
- Net Interest and Other Expense: Approximately $12 million .
- Tax Rate: Approximately 22% .
- Adjusted EPS: $1.10 to $1.14 for the third quarter .
Q1 2024 Earnings Call
- Issued Period: Q1 2024
- Guided Period: FY 2024
- Guidance:
- Organic Growth: 1% to 3% for the full year; decline in low single digits for Q2, positive growth in the second half .
- Revenue: Full year $2.76 billion to $2.82 billion .
- Operating Margins: Roughly flat at 28% for the year .
- Net Interest and Other Expenses: Approximately $60 million for the year .
- Tax Rate: Approximately 20% .
- Average Diluted Share Count: 123.5 million shares for the year .
- Adjusted EPS: $4.55 to $4.75 for the year .
- Free Cash Flow: Greater than $475 million for the year .
Q4 2023 Earnings Call
- Issued Period: Q4 2023
- Guided Period: FY 2024
- Guidance:
- Adjusted EPS: $4.55 to $4.75 .
- Organic Revenue Growth: 1% to 3%; first quarter down mid-single digits, positive growth in Q3 .
- Operating Margin: Flat at 28% for the year .
- Gross Margin: Roughly flat year-over-year .
- Adjusted Net Interest and Other Expense: Approximately $70 million .
- Tax Rate: Approximately 20% .
- Average Share Count: 123.5 million .
- Free Cash Flow: About $450 million; overall cash generation target of about $600 million .
- FX Impact: Approximately 1% contribution to total revenue .
- Diagnostics Segment: First half roughly flat, mid-single-digit growth in the second half .
- Immunodiagnostics in China: Mid-single-digit growth for the full year .
- Life Sciences Instruments and Applied Genomics: Down in the high single-digit range for 2024 .
Recent developments and announcements about RVTY.
Financial Actions
-
Nature of Obligation: The company has entered into a credit agreement involving multiple lenders, including Bank of America, JPMorgan Chase, and others, as part of a syndicated loan facility. This agreement includes provisions for loans, letters of credit, and other financial accommodations , ,.
-
Potential Financial Impact:
- The agreement establishes obligations under synthetic lease arrangements, receivables facilities, and other off-balance sheet arrangements ,.
- The company is required to maintain cash collateral under certain conditions, such as when a lender defaults or when outstanding obligations exceed specified limits.
- The agreement includes guarantees for all existing and future indebtedness of the company and its subsidiaries, which could significantly impact the company's financial health if obligations are triggered ,.
-
Effect on Financial Health:
- These obligations could increase the company's leverage and affect liquidity, especially if the company faces financial distress or defaults on its commitments.
- The agreement includes covenants and conditions that may restrict the company's operational flexibility and require compliance with financial ratios and reporting standards.
- Investors: Should monitor the company's debt levels and compliance with the agreement's terms to assess potential risks to equity value.
- Creditors: Need to evaluate the company's ability to meet its obligations under the agreement.
- Management: Must ensure adherence to the agreement's covenants to avoid penalties or defaults.
Debt Issuance
Revvity, Inc. (RVTY) has entered into a material definitive agreement that creates a direct financial obligation or an off-balance sheet arrangement.
Key Details:
Implications for Stakeholders:
This development underscores the importance of closely tracking Revvity's financial disclosures and performance metrics to understand the full impact of these obligations on its balance sheet and overall financial health.